Application Observation of Thyroid Cancer Panel in Nodule Differentiation and Precision Diagnosis and Treatment

Clinical Demand for Thyroid Nodule Risk Assessment

Thyroid nodules have a high detection rate in the general population, and most are benign, but some nodules still require comprehensive assessment combining cytology and molecular testing. As a testing panel targeting thyroid-related driver genes and fusion genes, the thyroid cancer panel is commonly used for auxiliary evaluation of nodules with indeterminate fine-needle aspiration cytology results, as well as for obtaining gene information related to postoperative pathological classification and prognosis. Compared with single-gene testing, a panel can simultaneously examine multiple loci in the same sample, reducing repeated sample consumption and providing more reference information for subsequent treatment decisions.

Gene Categories More Commonly Included in Panels

Currently, common thyroid cancer panels generally cover driver genes associated with types such as papillary thyroid carcinoma, follicular carcinoma, and medullary carcinoma. Loci including BRAF V600E, RAS family, RET fusion, PAX8/PPARG fusion, and TERT promoter mutation are often included in different product designs. The implications of different types of gene alterations in risk stratification are not the same; for example, when BRAF V600E and TERT promoter mutation coexist, it often indicates the need for more detailed follow-up evaluation. It should be noted that frequency data differ across study cohorts, and the locus combination of a panel is iterated according to guideline updates and technological advances.

Clinical Application Boundaries of Test Results

The results of a thyroid cancer panel should not be used as the sole basis for diagnosis, and clinical judgment is usually made comprehensively in combination with ultrasound features, cytology reports, patient age, and family history. For nodules with indeterminate cytology, molecular testing can provide a reference for risk assessment, but different guidelines differ in their statements regarding recommended scenarios and levels of evidence. In addition, variant classification, allele frequency, and drug sensitivity annotations in test reports all need to be interpreted by qualified professionals, avoiding directly equating test findings with treatment pathway selection.

Companion Diagnostics and Future Directions

With the expansion of indications for targeted drugs in thyroid cancer, some driver gene alterations have become reference indicators for drug selection. RET inhibitors, BRAF/MEK inhibitors, and others have shown certain promise in studies of different types of thyroid cancer, but drug use still needs to be based on approved indications and the comprehensive judgment of clinicians. Future panels may be further enriched in epigenetic markers, methylation signals, and immune microenvironment markers, providing more comprehensive information for preoperative stratification and postoperative management of thyroid cancer.